Inclusion Criteria

• Confirmation of diagnosis
• Relapsed or relapsed/refractory disease
• Age ≥ 18 years
• ECOG performance status (0-2)
• Life expectancy greater than 3 months
• Adequate bone marrow and renal functions
• Ability to comply with treatment, PK and test schedules
• At least one measurable lesion (NHL subjects) 

Exclusion Criteria

• Active plasma cell leukemia and/or leukemic manifestations of lymphoma
• Known amyloidosis (myeloma subjects)
• Chronic lymphocytic leukemia and Richter's transformation, and prolymphocytic leukemia (NHL subjects)
• T-cell malignancy
• Sensory or motor neuropathy ≥ grade 2
• Chronic or ongoing active infectious disease requiring systemic treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active hepatitis C
• Ongoing immunosuppressive therapy, including systemic corticosteroids. Note: Subjects may be using topical or inhaled corticosteroids
• Clinically significant cardiac disease
• Significant concurrent, uncontrolled medical condition
• History or clinical signs of meningeal or active CNS involvement
• Known severe chronic obstructive pulmonary disease or asthma
• History of significant cerebrovascular disease
• Known Human Immunodeficiency Virus seropositivity
• Positive serology for hepatitis B defined by a positive test for HBsAg
• Concurrent participation in another therapeutic treatment trial
• High screening liver function tests
• Prior treatment with CD74 targeting therapy
• Patients requiring anti-coagulant therapy